Eli Lilly & Co. is the first pharmaceutical stock to hit a $1 trillion valuation, with its stock’s rise driven by a methodical approach to capturing an obesity-drug market that didn’t exist five years ...

Eli Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by tech giants and underscoring its rise as a weight-loss powerhouse. A more ...

The booming market for weight-loss drugs has propelled Eli Lilly LLY-0.41%decrease; red down pointing triangle to become the first pharmaceutical company to hit $1 trillion in market capitalization, ...

The world’s largest drugmaker, Eli Lilly & Co., just notched another milestone: it’s the first health-care company to cross the $1 trillion threshold as investors bet big on the drugmaker’s ...

The 150-year-old drugmaker is the first company in health care to hit the milestone. By Rebecca Robbins Eli Lilly, the maker of hugely popular weight loss drugs, has reached $1 trillion in value, ...

Silicon Valley’s giants crowd the list of the world’s most valuable companies, but drugmaker Eli Lilly is hot on their heels. The company topped a market capitalization of $1 trillion on Friday, ...

Sen. Ruben Gallego (D-Ariz.) is asking for more information on Eli Lilly’s recently announced agreement with the Trump administration regarding the sale of its GLP-1 medication. In a letter to Lilly ...

Both Eli Lilly and Novo Nordisk are denying a telehealth company’s claim of having struck partnerships with the two companies to provide direct access to their popular obesity meds. Thursday morning, ...

This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them. From late 2020 to the summer of 2024, Eli Lilly & Co.

Eli Lilly stock reached a new 52-week high on Nov. 10, up 4.7% and extending a month-long rally of 16%, after the pharmaceutical giant announced two strategic deals, following the highly anticipated ...

Eli Lilly (LLY) has reached a research and licensing agreement worth up to $1.2B with SanegeneBio to develop and commercialize RNAi therapeutics for metabolic diseases, the Boston, Massachusetts-based ...

Weight loss drugs generated about $10 billion for Lilly in the most recent quarter. One particular hurdle for some patients, however, has been the price of these products. Medicare so far hasn't ...